78 related articles for article (PubMed ID: 6265401)
1. Quantitation of cell DNA in the evaluation of heteroploid cells as substrate for the preparation of killed viral vaccines.
Crainic R; Horodniceanu F; Barme M
Intervirology; 1980; 14(5-6):300-9. PubMed ID: 6265401
[TBL] [Abstract][Full Text] [Related]
2. Presence and quantification of cell substrate DNA in inactivated poliovirus vaccine.
Crainic R; Horodniceanu F; Barme M
Dev Biol Stand; 1980; 46():275-9. PubMed ID: 6245003
[TBL] [Abstract][Full Text] [Related]
3. Cell substrate and risk in killed poliomyelitis vaccine.
Horodniceanu F; Crainic R; Barme M
Dev Biol Stand; 1981; 47():35-9. PubMed ID: 6262159
[TBL] [Abstract][Full Text] [Related]
4. Detection and elimination of cellular nucleic acids in biologicals produced on continuous cell lines.
van Wezel AL; van der Marel P; van Beveren CP; Verma I; Salk PL; Salk J
Dev Biol Stand; 1981; 50():59-69. PubMed ID: 6281112
[TBL] [Abstract][Full Text] [Related]
5. PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.
Sanders BP; Edo-Matas D; Custers JH; Koldijk MH; Klaren V; Turk M; Luitjens A; Bakker WA; Uytdehaag F; Goudsmit J; Lewis JA; Schuitemaker H
Vaccine; 2013 Jan; 31(5):850-6. PubMed ID: 23123018
[TBL] [Abstract][Full Text] [Related]
6. Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier.
Montagnon BJ; Fanget B; Vincent-Falquet JC
Rev Infect Dis; 1984; 6 Suppl 2():S341-4. PubMed ID: 6740071
[TBL] [Abstract][Full Text] [Related]
7. Sequence studies of poliovirus RNA. III. Polyuridylic acid and polyadenylic acid as components of the purified poliovirus replicative intermediate.
Yogo Y; Wimmer E
J Mol Biol; 1975 Mar; 92(3):467-77. PubMed ID: 167176
[No Abstract] [Full Text] [Related]
8. Cell substrate for killed poliovaccine production.
Beale AJ
Dev Biol Stand; 1981; 47():19-23. PubMed ID: 6262147
[TBL] [Abstract][Full Text] [Related]
9. New trends in the preparation of cell substrates for the production of virus vaccines.
van Wezel AL
Prog Immunobiol Stand; 1971; 5():187-92. PubMed ID: 4349819
[No Abstract] [Full Text] [Related]
10. Present state and developments in the production of inactivated poliomyelitis vaccine.
van Wezel AL
Dev Biol Stand; 1981; 47():7-13. PubMed ID: 6262162
[TBL] [Abstract][Full Text] [Related]
11. The monitoring of antigen levels during inactivated poliovirus vaccine production: evaluation of filtration techniques.
Moynihan M; Petersen I
Dev Biol Stand; 1981; 50():243-8. PubMed ID: 6804290
[TBL] [Abstract][Full Text] [Related]
12. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines.
van Wezel AL; van Herwaarden JA; van de Heuvel-de Rijk EW
Dev Biol Stand; 1979; 42():65-9. PubMed ID: 223923
[TBL] [Abstract][Full Text] [Related]
13. Marker studies of poliovirus.
Cossart YE
Nature; 1966 Sep; 211(5056):1432. PubMed ID: 4291100
[No Abstract] [Full Text] [Related]
14. New approach to the production of concentrated and purified inactivated polio and rabies tissue culture vaccines.
van Wezel AL; van Steenis G; Hannik CA; Cohen H
Dev Biol Stand; 1978; 41():159-68. PubMed ID: 223908
[TBL] [Abstract][Full Text] [Related]
15. Improved ELISA test for determination of potency of Inactivated Poliovirus Vaccine (IPV).
Rezapkin G; Dragunsky E; Chumakov K
Biologicals; 2005 Mar; 33(1):17-27. PubMed ID: 15713553
[TBL] [Abstract][Full Text] [Related]
16. The purification of virus vaccines.
Norrby E
Lab Pract; 1970 Jan; 19(1):54-7 passim. PubMed ID: 4907062
[No Abstract] [Full Text] [Related]
17. Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine.
Sanders BP; Edo-Matas D; Papic N; Schuitemaker H; Custers JHHV
Vaccine; 2015 Oct; 33(42):5498-5502. PubMed ID: 26362098
[TBL] [Abstract][Full Text] [Related]
18. Viral vaccines and residual cellular DNA.
Horaud F
Biologicals; 1995 Sep; 23(3):225-8. PubMed ID: 8527122
[TBL] [Abstract][Full Text] [Related]
19. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
Rezapkin G; Martin J; Chumakov K
Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
[TBL] [Abstract][Full Text] [Related]
20. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
